Colorectal Cancer Biomarkers
Key Points
Key Points
Current evidence-based recommendations for the molecular testing of CRC tissues to guide EGFR-targeted therapies and conventional chemotherapy regimens were developed through collaboration of four societies: American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO).
Diagnosis
...iagnosi...
...rcinoma patients being considered for anti-EGFR...
...AF c. 1799 (p.V600) mutational analysis...
...AF p.V600 mutational analysis should be performed...
...icians should order mismatch repair status te...
...s insufficient evidence to recommend BRAF c.1799...
...here is insufficient evidence to recom...
...nsufficient evidence to recommend PTEN a...
...c or recurrent colorectal carcinom...
...rmalin fixed paraffin embedded tissue is a...
...must use validated colorectal carcinoma mole...
...of molecular biomarker testing fo...
...ies must validate the performance of IHC testing...
...aboratories must provide clinically appropriate tu...
...d IHC biomarker testing in colorectal carc...
...ies should establish policies to ensure efficie...
...f the patient’s medical team, inclu...
...ratories that require send out of tests for treatm...
...ogists must evaluate candidate specimens for...
...hould use colorectal carcinoma mole...
...lorectal carcinoma molecular biomarker results sh...
Colorectal carcinoma molecular biomarke...
...s must incorporate colorectal carcinom...
.... Outcomes of RAS Mutations and Anti-EGFR Thera...
...e 2. Concordance Rates Between Primary and...